Hansoh Pharma's Ameile approved in China for lung cancer

China’s National Medical Products Administration (NMPA) has granted marketing authorization for Ameile (almonertinib, previously also known as HS-10296) once daily tablets for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), who have progressed on or after other EGFR tyrosine kinase inhibitor (TKI) therapy.

Developed by Chinese biotech Hansoh Pharmaceutical Group (HKG: 3692), Ameile is the second third-generation EGFR TKI to be approved for metastatic NSCLC patients with EGFR T790M. The approval of Ameile provides a highly efficacious treatment option with favorable safety profile for advanced NSCLC patients.

Surprisingly, Hansoh’s shares closed down 6.9% to HK$25.60, but the Han Seng Index was also down.